GUILLERMO MARIA LOPEZ VIVANCO-rekin lankidetzan egindako argitalpenak (43)

2021

  1. Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial

    Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 8

  2. First-line osimertinib in patients with epidermal growth factor receptor–mutant non–small-cell lung cancer and with a coexisting low allelic fraction of Thr790Met

    European Journal of Cancer, Vol. 159, pp. 174-181

  3. Phase II clinical trial of nab-paclitaxel plus gemcitabine in elderly patients with previously untreated locally advanced or metastatic pancreatic adenocarcinoma: the BIBABRAX study

    Cancer Chemotherapy and Pharmacology, Vol. 87, Núm. 4, pp. 543-553

  4. Pretreatment tissue TCR repertoire evenness is associated with complete pathologic response in patients with NSCLC receiving neoadjuvant chemoimmunotherapy

    Clinical Cancer Research, Vol. 27, Núm. 21, pp. 5878-5890

2020

  1. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial

    The Lancet Oncology, Vol. 21, Núm. 11, pp. 1413-1422

2019

  1. Association of PALB2 Messenger RNA Expression with Platinum-Docetaxel Efficacy in Advanced Non–Small Cell Lung Cancer

    Journal of Thoracic Oncology, Vol. 14, Núm. 2, pp. 304-310

  2. Germline c.1A>C heterozygous pathogenic variant in SDHA reported for the first time in a young adult with a gastric gastrointestinal stromal tumour (GIST): A case report

    Hereditary Cancer in Clinical Practice, Vol. 17, Núm. 1

2018

  1. Aportación del uso medicinal de los derivados del cannabis: una revisión de su potencial eficacia clínica y riesgos

    Gaceta médica de Bilbao: Revista oficial de la Academia de Ciencias Médicas de Bilbao. Información para profesionales sanitarios, Vol. 115, Núm. 2, pp. 83-95

  2. Comparison of plasma ctDNA and tissue/cytology-based techniques for the detection of EGFR mutation status in advanced NSCLC: Spanish data subset from ASSESS

    Clinical and Translational Oncology, Vol. 20, Núm. 10, pp. 1261-1267

  3. Contribution of the medicinal use of cannabis derivatives: A review of their potential clinical efficacy and risks

    Gaceta Medica de Bilbao, Vol. 115, Núm. 2, pp. 83-95

  4. Infective endocarditis in a patient with metastatic colorectal cancer

    Revista Espanola de Quimioterapia

  5. Long-term response to first-line bevacizumab-based therapy in patients with metastatic breast cancer: Results of the observational “LORENA” study

    OncoTargets and Therapy, Vol. 11, pp. 5845-5852

2017

  1. Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC

    Journal of the National Cancer Institute, Vol. 109, Núm. 9

  2. Cost minimization analysis of treatment with intravenous or subcutaneous trastuzumab in patients with HER2-positive breast cancer in Spain

    Clinical and Translational Oncology, Vol. 19, Núm. 12, pp. 1454-1461

  3. Epithelial ovarian cancer and primary peritoneal carcinomatosis in the elderly: What is our clinical practice?

    European Journal of Gynaecological Oncology, Vol. 38, Núm. 5, pp. 695-699

  4. Hereditary pancreatic cancer: Related syndromes and clinical perspective

    Hereditary Cancer in Clinical Practice, Vol. 15, Núm. 1

2016

  1. 147P: Level of concordance between EGFR mutation status obtained from tissue/cytology and blood (plasma) for advanced non-small-cell lung cancer in Spain: ASSESS study

    Journal of Thoracic Oncology, Vol. 11, Núm. 4, pp. S122

  2. Nab-Paclitaxel in metastatic breast cancer: Defining the best patient profile

    Current Cancer Drug Targets, Vol. 16, Núm. 5, pp. 415-428

  3. Treatment patterns of adjuvant interferon-α2b for high-risk melanoma: A retrospective study of the Grupo Español Multidisciplinar de Melanoma - Prima study

    Melanoma Research, Vol. 26, Núm. 3, pp. 278-283

2015

  1. BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer

    Scientific Reports, Vol. 5